Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Operating Expenses (2020 - 2025)

Viridian Therapeutics, Inc.\DE has reported Other Operating Expenses over the past 6 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly results put Other Operating Expenses at -$2.1 million for Q4 2025, down 726.56% from a year ago — trailing twelve months through Dec 2025 was -$1.7 million (down 268.74% YoY), and the annual figure for FY2025 was -$1.7 million, down 427.71%.
  • Other Operating Expenses for Q4 2025 was -$2.1 million at Viridian Therapeutics, Inc.\DE, down from $453000.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for VRDN hit a ceiling of $33.7 million in Q4 2022 and a floor of -$2.1 million in Q4 2025.
  • Median Other Operating Expenses over the past 3 years was -$195000.0 (2024), compared with a mean of $6.3 million.
  • Peak annual rise in Other Operating Expenses hit 332.31% in 2025, while the deepest fall reached 726.56% in 2025.
  • Viridian Therapeutics, Inc.\DE's Other Operating Expenses stood at $33.7 million in 2022, then tumbled by 100.76% to -$256000.0 in 2024, then crashed by 726.56% to -$2.1 million in 2025.
  • The last three reported values for Other Operating Expenses were -$2.1 million (Q4 2025), $453000.0 (Q3 2025), and -$256000.0 (Q4 2024) per Business Quant data.